Loading...
01/10 17:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance with a 27% revenue increase and significant growth in Deep TMS system shipments. The company is expanding internationally and maintaining robust margins. Despite geopolitical risks and supply chain concerns, management remains optimistic, supported by positive clinical data and market expansion strategies. The lack of a share repurchase program is a minor negative, but overall, the guidance and financial health suggest a positive market reaction over the next two weeks.
Revenue $11.5 million, a 27% increase compared to $9.1 million in Q1 2024.
Gross Profit $8.6 million, maintaining a 75% gross margin, compared to $6.8 million in Q1 2024.
Operating Profit Approximately $576,000, compared to approximately $93,000 in Q1 2024.
Adjusted EBITDA About $1.3 million, compared to $715,000 in Q1 2024.
Net Profit About $1.1 million, compared to $111,000 in Q1 2024.
Cash and Cash Equivalents Approximately $72 million as of March 31, 2025.
Sales and Marketing Expenses $4.2 million, compared to $3.8 million in Q1 2024.
Research and Development Expenses $2.3 million, compared to $1.6 million in Q1 2024.
General and Administrative Expenses $1.5 million, compared to $1.3 million in Q1 2024.
Revenue Growth: Generated $11.5 million in revenue, marking a 27% increase year-over-year.
Deep TMS Systems Shipped: Shipped a total of 81 Deep TMS systems, representing a 42% increase compared to Q1 2024.
Backlog and Performance Obligation: Signed a backlog and remaining performance obligation totaling nearly $60 million.
Clinical Indications: First TMS therapy approved for OCD and the first cleared for anxious depression.
Market Expansion: Commercial growth particularly in the U.S. driven by extended adoption of Deep TMS for OCD and anxious depression.
Global Expansion: Working to broaden patient access through global expansion and health system integration.
Gross Margin: Reported a strong gross margin of 75%.
Operating Income: Increased operating income and adjusted EBITDA margin.
Expense Management: Balanced expense management while generating high revenue growth.
Sales Strategy: Focused on strengthening customer base and engaging large enterprise networks with multi-year agreements.
R&D Roadmap: Advancing R&D roadmap to unlock new and expanded treatment indications.
Accelerated Treatment Protocol: Advancing a clinical trial for an accelerated treatment protocol for major depressive disorder.
Geopolitical Risks: The company is actively monitoring potential exposure to recent changes in international trade and tariff policies, particularly concerning the U.S., Israel, and the European Union.
Supply Chain Challenges: The company acknowledges the impact of shifting market conditions due to geopolitical factors, which may affect supply chain operations.
Regulatory Issues: The company is working to expand reimbursement for PTSD treatment in Israel, indicating potential regulatory challenges in gaining broader acceptance and integration of their technology.
Economic Factors: The company does not anticipate a material impact on gross margin for the current year due to the fluid nature of trade policies, but remains cautious about economic conditions.
Revenue Growth: In Q1 2025, BrainsWay generated $11.5 million in revenue, marking a 27% increase year-over-year.
Deep TMS Systems: Shipped 81 Deep TMS systems in Q1 2025, a 42% increase compared to Q1 2024.
Backlog: Signed a backlog and remaining performance obligation totaling nearly $60 million.
Sales Strategy: Focused on strengthening customer base through multi-year agreements and enhancing customer service.
Market Positioning: Plans to elevate market awareness of Deep TMS, advance R&D roadmap, and broaden patient access.
Clinical Data: Data shows over 60% of patients respond positively to Deep TMS therapy for OCD.
International Expansion: Working to expand reimbursement for PTSD in Israel and increase access to Deep TMS.
2025 Revenue Guidance: Reiterating full year 2025 revenue guidance of $49 million to $51 million, representing 20% to 24% growth over 2024.
Operating Income Guidance: Anticipating operating income of 3% to 4% for full year 2025.
Adjusted EBITDA Guidance: Expecting adjusted EBITDA of 11% to 12% for full year 2025.
Share Repurchase Program: None
The company demonstrates strong financial performance with increased revenue, gross profit, and net profit. The positive cash flow and substantial cash reserves further enhance financial stability. The raised revenue guidance and promising market expansion initiatives are optimistic. The Q&A section reveals potential growth through accelerated protocols and minority investments, despite some management ambiguity. Overall, the company's strategic investments and market expansion efforts indicate a positive outlook, likely resulting in a stock price increase within the 2% to 8% range.
The earnings call presented strong financial performance with a 26% revenue increase, robust gross profit margins, and a significant net profit rise. The Q&A section highlighted positive developments like potential FDA clearance, strategic financing, and successful collaborations. Despite increased expenses, efficient cost management and strong cash position support financial health. The reiterated revenue guidance and strategic expansions further bolster a positive outlook. Given these factors, the stock price is likely to experience a positive movement in the short term.
The earnings call reflects strong financial performance with a 27% revenue increase and significant growth in Deep TMS system shipments. The company is expanding internationally and maintaining robust margins. Despite geopolitical risks and supply chain concerns, management remains optimistic, supported by positive clinical data and market expansion strategies. The lack of a share repurchase program is a minor negative, but overall, the guidance and financial health suggest a positive market reaction over the next two weeks.
The company reported strong financial performance with a significant increase in revenue and profitability, alongside optimistic guidance. The Q&A highlighted high demand and potential growth in OCD and MDD treatments. While there are risks like regulatory scrutiny and supply chain challenges, the positive market response to new product developments and stable gross margins contribute to a favorable outlook. Despite the lack of a shareholder return plan, the overall sentiment is positive due to the promising market potential and financial health.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
